New CEO will lead Impel’s unique CNS pipeline to the clinic and potential commercialization Seattle, WA—October 03, 2017—Impel NeuroPharma, Inc., a Seattle based biotechnology company, announced the appointment of veteran biotech executive Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Impel is developing first-in-class intranasal drug...

At the beginning of September, Impel NeuroPharma moved its headquarters to 201 Elliot, a new biotech lab and office building. “The office gives us capacity to grow, it takes us from startup mode to small company mode.” Dr. John Hoekman, Impel's CEO is quoted as saying in an article from the...

The U.S. Patent and Trademark Office (USPTO) has issued to Impel NeuroPharma, Inc. a patent relating to the company's POD™ device. Patent number 9,550,036, entitled "NASAL DRUG DELIVERY DEVICE," is directed to a device for delivery of compounds to the nasal cavity and methods of using the same.   Impel is...

March 03, 2017 05:00 AM Eastern Standard Time SEATTLE--(BUSINESS WIRE)--Impel NeuroPharma, a Seattle-based clinical-stage biotechnology company developing first-in-class intranasal drug treatments, announced today the appointment of Timothy S. Nelson as Independent Director of the Board of Directors. Mr. Nelson has over 20 years of experience with drug delivery, medical devices and drug...

SEATTLE, Feb. 7, 2017 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced today that it has entered into service agreements with Camargo Pharmaceutical Services, LLC. Camargo will be providing end-to-end regulatory consulting and strategic development services for Impel's pipeline of drug-device combination...

Development of neurological and mental health drugs often requires pre-clinical testing in multiple pre-clinical models to demonstrate efficacy and safety and to elucidate mechanisms. Drug delivery to the central nervous system (CNS) to target neurological diseases is particularly problematic because the blood-brain barrier (BBB) prevents most compounds from reaching the...

The Centre for Addiction and Mental Health (CAMH) and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. This novel treatment is a peptide that disrupts two dopamine receptors that bind at higher rates in the brains of people...